Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke
Controlled trialOther animals
- Design
- Controlled trial
- Subjects
- not stated in abstract (rats)
- Dose used in the study
- not stated in abstract (intravenous, described as dose-dependent)
- Duration
- single treatment given up to 6 hours (transient occlusion) or 9 hours (permanent occlusion) after stroke onset; outcomes followed to day 14
- What was measured
- Infarct histology, motor and sensory deficits to day 14, organ histology, complete blood count, coagulation tests and serum chemistry in rats with permanent or transient middle cerebral artery occlusion; mechanism assays in cell culture and brain homogenates.
What the authors reported
The authors report dose-dependent cerebroprotection with intravenous carnosine, with histological and functional benefits sustained to day 14, and therapeutic windows of 6 hours in the transient model and 9 hours in the permanent model. They report no adverse effects or toxicity; organ histology, blood counts, coagulation and serum chemistry showed no abnormalities. In cell culture and brain homogenates they describe anti-excitotoxic, antioxidant and mitochondria-protecting activity. They call carnosine a strong candidate for further stroke treatment development.
Limits of this study
Rat model with intravenous dosing; doses and group sizes are not given in the abstract. Full text not read.
Source
PubMed 23250994 · doi:10.1161/STROKEAHA.112.673954
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.